ArticleScientific reports2023

Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis.

Hyung-Jun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.